Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00342485 · ClinicalTrials.gov registry record
In Vitro Study of Peripheral Blood Mononuclear Cell Function in Healthy Individuals and Patients
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 5,000
- Enrollment target
NCT00342485: Completed study, sponsored by National Cancer Institute (NCI).
NCT00342485 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 5,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00342485 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 5,000 participants
- Enrollment target
Study Summary
Peripheral blood mononuclear cells (PBMC) will be collected from healthy volunteers and patients who present with different diseases that involve or implicate the immune system dysregulation (HIV infection, autoimmune diseases and cancer). These PBMC will be studied in vitro for a number of functional parameters, including generating soluable factors that inhibit HIV infection, developing patterns of immune dysregulation, and inducing apoptotic T cell death. The purpose of such studies is to obtain insight into the mechanisms of natural resistance to viral infections, AIDS pathogenesis, and disease-induced immune dysregulation.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 1993-04-12 |
| Est. Completion | 2008-03-03 |
What the finished NCT00342485 record still lists
NCT00342485 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00342485 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00342485 about?
NCT00342485 is a clinical study titled "In Vitro Study of Peripheral Blood Mononuclear Cell Function in Healthy Individuals and Patients". Peripheral blood mononuclear cells (PBMC) will be collected from healthy volunteers and patients who present with different diseases that involve or implicate the immune system dysregulation (HIV infection, autoimmune diseases and cancer). These PBMC will be studied in vitro for a number of function...
What is the current status of trial NCT00342485?
This trial is currently completed. The enrollment target is 5,000 participants. The study started on 1993-04-12. Estimated completion is 2008-03-03.
Who is sponsoring clinical trial NCT00342485?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI